Our study shows that the participating Spanish laboratories had an overall acceptable proficiency in detecting VRE but that a substantial proportion of VRE isolates with low or intermediate levels of resistance were not detected. We recommend that studies be conducted to validate laboratory proficiency testing as an important step in the prevention and control of the spread of antimicrobial resistance.
Enterococci are major nosocomial pathogens and have been isolated from 9% of nosocomial bloodstream, 12% of surgical site, and 16% of urinary tract infections reported by U.S. hospitals participating in the hospital-wide component of the National Nosocomial Infections Surveillance (NNIS) system (13) . In the face of the increasing incidence of high-level resistance to penicillin and aminoglycosides, enterococci resistant to all three antimicrobial agents (penicillin, aminoglycosides, and vancomycin) with activity against enterococci pose a serious challenge not only for clinicians but also for health care institutions, because numerous nosocomial outbreaks have been reported (10, 11) . Moreover, enterococci may be a reservoir for resistance genes for other gram-positive organisms, including Staphylococcus aureus; in vitro studies have shown that the vanA gene coding for vancomycin resistance can be transferred from enterococci to S. aureus (14) . Prevention and control of the spread of vancomycin-resistant enterococci (VRE) are therefore major national and international public health challenges. Specific guidelines and recommendations for preventing the spread of VRE were published in 1995 by the Centers for Disease Control and Prevention (CDC) and its Hospital Infection Control Practices Advisory Committee (3) . Despite this, 40% of hospitals participating in NNIS reported the detection of one or more isolates of VRE in 1996, and the proportion of enterococci resistant to vancomycin at hospitals participating in NNIS has continued to increase to 22.6.% among intensive care unit patients and 16.5% among nonintensive care patients in 1997 (4) . The first step in controlling the spread of VRE is its early detection. Nevertheless, detection of the intermediate-and low-level resistance exhibited by strains with the vanB and vanC phenotypes is not consistently done by automated commercial methods (15) . Different studies in the United States and Argentina have shown that only 16 to 27% of these isolates are correctly identified (6, 16) .
Little is known about the epidemiology of VRE in Europe. Several hospital-based reports suggest low prevalence rates of VRE in clinical specimens (9, 17) . In Spain, an annual nationwide point prevalence study demonstrated a stable prevalence rate of approximately 10% for enterococcal nosocomial infections; however, no data on VRE were collected (8) . During 1994 and 1995, in three hospitals in Madrid, Spain, vancomycin resistance was found among 8 of 100 (8%) enterococcal isolates cultured from blood (1) . In 1994, the European Glycopeptide Susceptibility Survey presented unpublished data suggesting problems in the testing of the susceptibilities of various gram-positive isolates to glycopeptides (7) . However, no isolates with low-level or intermediate-to low-level vancomycin resistance were tested, and no final results or information on the laboratory susceptibility test methods used have been published. To date, no study of the proficiency of detection of VRE in clinical laboratories in Spain has been conducted. In the study described here, we sought to assess the ability of clinical laboratories in Spain to detect VRE.
MATERIALS AND METHODS
Bacterial strains. Five enterococcal isolates were obtained from the CDC strain collection and were coded as organisms 1 through 5, respectively. The isolates included two Enterococcus faecium isolates, one Enterococcus faecalis isolate, and one Enterococcus gallinarium isolate, with each isolate having one of the four most common vancomycin-resistant phenotypes. In addition, E. faecalis ATCC 29212, which is susceptible to vancomycin, penicillin, and ampicillin, was included ( Table 1) .
The isolates were inoculated onto nutrient agar slants (Becton Dickinson Microbiology Systems, Cockeysville, Md.), incubated for 24 h, and distributed to the participating clinical laboratories along with standardized susceptibility test result forms. The participating laboratories were blinded as to the species and the antimicrobial susceptibility patterns of the isolates. Each participant was instructed to test the five isolates for their susceptibilities to vancomycin by their routine laboratory procedures and to report the zone size or MIC. Additionally, the participating laboratories were asked to provide hospital characteristics, the number and proportion of enterococci and isolates of VRE detected in the preceding year, the routine antimicrobial susceptibility method(s) used, and whether the E test and agar screening tests were routinely used. After completion of testing, the forms were completed and returned to CDC for data entry and analysis. Testing at CDC was by National Committee for Clinical Laboratory Standards (NCCLS) reference methods (12) . The MIC and/or zone size results from participants and CDC were compared. Testing errors were classified as either very major, major, or minor errors. A very major error occurred when the CDC method determined that an organism was resistant to an antimicrobial agent and the method used by the participant reported that it was susceptible to that agent. A major error occurred when the CDC method found that an organism was susceptible and the method used by the participant found that it was resistant. A minor error occurred when the CDC method determined that an organism was susceptible or resistant to an antimicrobial agent and the method used by the participant reported that it was intermediate or when the CDC method determined that an organism was intermediate and the participant reported that it was resistant or susceptible.
Reference methods. Disk diffusion testing at CDC was performed as described previously (16) . Isolates were defined as susceptible, intermediate, or resistant by using NCCLS criteria (12) . The strains were tested for the presence of the vanA, vanB, and vanC genes by PCR reaction as described previously (5) .
RESULTS
Participating hospitals' characteristics. Of 57 hospital laboratories contacted, 27 (47%) agreed to participate in the study. Five participants did not provide the MIC or zone size; data from these laboratories were excluded from the analysis (Table 2) . Overall, the participating hospitals were small (Ͻ400 beds; n ϭ 10) or medium (400 to 600 beds; n ϭ 7) in size. Of 14 hospitals, 8 (57%) were not affiliated with a university. All participants routinely tested enterococcal isolates from blood for vancomycin resistance, and the majority routinely tested enterococcal isolates from urine for vancomycin resistance. Participating hospitals used a variety of vancomycin susceptibility testing methods ( Table 3 ). The ␤-lactamase test was routinely performed in 11 of 22 (50%) laboratories. In contrast, agar screening was never used, and the E test was used very infrequently (1 of 22 [4.5%] ). In 1994, 7,469 enterococci were isolated at the participating laboratories. The median prevalence rate of VRE for the 20 participants reporting these data was 0.25% (range, 0 to 9%). In 10 of these 20 (50%) hospitals, no VRE isolates had been detected. VRE were not significantly more likely to be isolated at hospitals with Ͼ600 beds than at hospitals with Յ600 beds.
Vancomycin resistance. Overall, the participating laboratories accurately determined vancomycin resistance in 61 of 88 (69.3%) instances. This rate varied with the level of vancomycin resistance (Table 3 
DISCUSSION
The laboratory serves as the first step in the prevention and control of the spread of antimicrobial resistance. To accurately detect antimicrobial agent-resistant strains, proficiency is essential. Previous studies have documented difficulties in detecting in the clinical setting strains of enterococci with low or intermediate levels of vancomycin resistance (6, 7, 16) . Misclassification of an isolate as susceptible (minor errors for intermediate vancomycin-resistant strains and very major errors) has serious implications for both the clinical management of patients and the adequacy of any antimicrobial resistance surveillance system. On the other hand, misclassification of an isolate as at least intermediate resistant (major errors and minor errors for resistant isolates) has less serious consequences for the clinical management of patients but overestimates the number of isolates with at least an intermediate level of resistance. The control of the spread of VRE will be more difficult if more isolates are misclassified as vancomycin susceptible. However, overestimation of the number of VRE isolates adds expenses for unnecessary prevention and control measures.
Overall, the Spanish clinical laboratories participating in this study correctly identified VRE in 61 of 88 (69.3%) instances. These results are better than those obtained in the New Jersey (58.5%) or Argentine-U.S. (60%) studies (6, 16) . Similar to those studies, proficiency varied by level of vancomycin resistance, and most participating laboratories had difficulty in detecting isolates with low and intermediate levels of resistance. Improvement was noted, however, in the detection of vancomycin resistance in isolates with the VanB2 and VanB phenotypes. Previously reported rates of detection of these organisms have ranged from 29 to 50 and 38 to 50%, respectively. These rates are lower than the rates of 59.19 and 77.3%, respectively, in the present study. Results with the organism of the VanB phenotype are particularly reassuring, because the proportion of these clinical isolates is increasing (2) . Misclassification of vancomycin-resistant isolates as vancomycin susceptible occurred in 16 of 88 (18.2%) instances, which represents a definitive improvement compared to the rates in former studies performed in the United States and Argentina (approximately 30% rate of misclassification as vancomycin susceptible in both countries). Our results are even better, if we consider only the results of methods used by at least three participants (8 of 68 [11.8%] instances). Misclassification to vancomycin susceptible accounted for the majority of errors (16 of 27 [59.3%] errors). However, half of these occurred with organism 3 (E. gallinarum phenotype VanC), which accounts for only 5 to 10% of clinical isolates and which, to date, has not been implicated in nosocomial outbreaks (2, 5) . Thus, the impact of these misclassification errors on the total number of VRE missed is minimal. Very major errors are worrisome. In this study, they were seen in 3.4% of the instances. They tended to occur by methods used by a very small number of laboratories.
All comparisons between methods must be made with caution. This study was designed to evaluate proficiency in the detection of vancomycin resistance by participating clinical laboratories and not to evaluate the proficiencies of the diagnostic methods. Therefore, we did not collect information on innoculum size, incubation time, or the controls used at these facilities to standardize the test procedures, but rather, we asked the participants to test the isolates by their routine laboratory techniques. Differences in those factors might explain differences in performance.
Automated MIC determination methods were most commonly used by participating Spanish clinical laboratories (20 of 22 [90.9%]). All methods had difficulty in detecting intermediate or low levels of resistance. However, the accuracy varied by the method. When the analysis was limited to methods used by at least three laboratories, the Microscan Walkaway and Microscan Autoscan systems yielded the most accurate and consistent results. For tests with isolates with at least an intermediate level of resistance, their overall error rates were 5 of 36 (13.9%) and 2 of 12 (16.7%) instances, respectively. Half of their errors were within onefold dilution, and no isolate with vancomycin resistance mediated by vanA and vanB was misclassified as susceptible. Moreover, of 10 participating laboratories with no errors, 9 (90%) used these methods. Finally, errors by Microscan users were clustered among 5 of 12 (41.6%) participants, which suggests some differences in local factors not related to the method. When compared with the study performed in New Jersey (16), our results for Microscan users were much better (Walkaway error rate, 13.9 versus 50.5%; Autoscan error rate, 16.7 versus 51.9%). Improvements in the software may explain this improved proficiency. In contrast, the broth-based method, i.e., the Pasco system, performed poorly at the five participating laboratories that used this method. The Pasco system has previously been reported to be highly accurate, and as stated above, this difference in performance might be partly explained by differences in local factors such as innoculum size, incubation time, or the controls used at these facilities.
The rates of incidence or prevalence of VRE in Spain and most countries in Europe are unknown. The very few published studies suggest low VRE prevalence rates. In our study, the participating laboratories reported very low annual prevalence rates (median, 0.25%; range, 0 to 9%), with 10 of 20 (50%) participants reporting no VRE isolates. However, those hospitals reporting no VRE isolates misclassified enterococcal isolates with at least an intermediate level of vancomycin resistance as vancomycin susceptible in 8 of 40 (20%) instances.
Therefore, VRE prevalence rates may be underestimated at the participating laboratories.
There are several limitations to our study. First, the participating laboratories are not a representative sample of all clinical laboratories in Spain. Therefore, we cannot estimate the magnitude of underreporting of the prevalence of VRE related to inadequate proficiency in laboratory detection in Spain. Second, because some methods were used by only a small number of participants, any comparison between methods must be made with great caution.
In conclusion, the Spanish laboratories that participated in this study showed an overall acceptable proficiency in detecting VRE and provided more accurate results than those provided by other laboratories in similar studies in other countries (6, 16) . However, our results suggest the possibility of a substantial underestimation of VRE prevalence rates as a result of an inability to detect low and intermediate levels of vancomycin resistance. As in previous studies, all antimicrobial susceptibility testing methods demonstrated difficulties in detecting isolates with intermediate and low levels of vancomycin resistance. However, the current Microscan Walkaway and Microscan Autoscan methods demonstrated improved proficiency compared to those demonstrated in former studies and to those of the other methods used in this study. Moreover, our study documented that a substantial proportion of the errors clustered in a few laboratories; it is hoped that feedback of our results will enhance the proficiencies of those laboratories. It is encouraging that most errors were those with limited clinical significance. We recommend that studies be conducted to validate laboratory proficiency testing as an important step in the prevention and control of antimicrobial resistance. 
